RHYTHM PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Debt Securities, Available-for-sale, Amortized Cost of $265.59 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $265.59M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $278.43M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $334.05M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $363.49M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $265.59M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $278.43M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $334.05M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $363.49M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $155.45M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $208.31M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $231.33M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $250.35M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $157.56M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $147.74M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $215.49M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $234.84M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $137.91M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $184.95M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $205.70M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $163.05M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $122.99M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $163.06M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $235.61M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $235.96M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $298.79M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $317.54M 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $71.89M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $133.88M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $168.90M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $201.57M 10-Q · filed 2020-05-04 | |
| 2019-12-31 | $230.16M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $90.72M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $131.93M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $179.50M 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $202.65M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $214.14M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $77.07M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $93.29M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $113.99M 10-K · filed 2019-03-08 | $113.85M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |